Search Results - "Chye, De Hoe"

Neutralization escape of emerging subvariants XBB.1.5/1.9.1 and XBB.2.3 from current therapeutic monoclonal antibodies by Chye, De Hoe, Chew, Charmaine W Y, Yeo, He Ping, Tambyah, Paul A, Young, Barnaby E, Tan, Gladys G Y, Tan, Boon Huan, Vasoo, Shawn, Chan, Conrad E Z

Get full text

The Cellular Characterization of SARS-CoV-2 Spike Protein in Virus-Infected Cells Using the Receptor Binding Domain Binding Specific Human Monoclonal Antibodies by Chan, Conrad En-Zuo, Ng, Ching-Ging, Lim, Angeline Pei-Chew, Seah, Shirley Lay-Kheng, Chye, De-Hoe, Wong, Steven Ka-Khuen, Lim, Jie-Hui, Lim, Vanessa Zi-Yun, Lai, Soak-Kuan, Wong, Pui-San, Leong, Kok-Mun, Liu, Yi-Chun, Sugrue, Richard J., Tan, Boon-Huan

“…A human monoclonal antibody panel (PD4, PD5, PD7, SC23, and SC29) was isolated from the B cells of convalescent patients and used to examine the S protein in…”
Get full text

IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development by Blasiak, Agata, Lim, Jhin Jieh, Seah, Shirley Gek Kheng, Kee, Theodore, Remus, Alexandria, Chye, De Hoe, Wong, Pui San, Hooi, Lissa, Truong, Anh T. L., Le, Nguyen, Chan, Conrad E. Z., Desai, Rishi, Ding, Xianting, Hanson, Brendon J., Chow, Edward Kai‐Hua, Ho, Dean

“…The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded largely…”
Get full text

The IDentif.AI-x pandemic readiness platform: Rapid prioritization of optimized COVID-19 combination therapy regimens by Blasiak, Agata, Truong, Anh T. L., Remus, Alexandria, Hooi, Lissa, Seah, Shirley Gek Kheng, Wang, Peter, Chye, De Hoe, Lim, Angeline Pei Chiew, Ng, Kim Tien, Teo, Swee Teng, Tan, Yee-Joo, Allen, David Michael, Chai, Louis Yi Ann, Chng, Wee Joo, Lin, Raymond T. P., Lye, David C. B., Wong, John Eu-Li, Tan, Gek-Yen Gladys, Chan, Conrad En Zuo, Chow, Edward Kai-Hua, Ho, Dean

“…IDentif.AI-x, a clinically actionable artificial intelligence platform, was used to rapidly pinpoint and prioritize optimal combination therapies against…”
Get full text

Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine by Skibinski, David A G, Hanson, Brendon J, Lin, Yufang, von Messling, Veronika, Jegerlehner, Andrea, Tee, Jason Boon Sern, Chye, De Hoe, Wong, Steven K K, Ng, Amanda A P, Lee, Hui Yin, Au, Bijin, Lee, Bernett T K, Santoso, Lucia, Poidinger, Michael, Fairhurst, Anna-Marie, Matter, Alex, Bachmann, Martin F, Saudan, Philippe, Connolly, John E

“…Influenza pandemics can spread quickly and cost millions of lives; the 2009 H1N1 pandemic highlighted the shortfall in the current vaccine strategy and the…”
Get full text

IDentif . AI : Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐Cov‐2) with digital drug development by Blasiak, Agata, Lim, Jhin Jieh, Seah, Shirley Gek Kheng, Kee, Theodore, Remus, Alexandria, Chye, De Hoe, Wong, Pui San, Hooi, Lissa, Truong, Anh T. L., Le, Nguyen, Chan, Conrad E. Z., Desai, Rishi, Ding, Xianting, Hanson, Brendon J., Chow, Edward Kai‐Hua, Ho, Dean

“…Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) led to multiple drug repurposing clinical trials that have yielded…”
Get full text

The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody by Chan, Conrad E. Z, Seah, Shirley G. K, Chye, De Hoe, Massey, Shane, Torres, Maricela, Lim, Angeline P. C, Wong, Steven K. K, Neo, Jacklyn J. Y, Wong, Pui San, Lim, Jie Hui, Loh, Gary S. L, Wang, Dongling, Boyd-Kirkup, Jerome D, Guan, Siyu, Thakkar, Dipti, Teo, Guo Hui, Purushotorman, Kiren, Hutchinson, Paul E, Young, Barnaby E, Low, Jenny G, MacAry, Paul A, Hentze, Hannes, Prativadibhayankara, Venkateshan S, Ethirajulu, Kantharaj, Comer, Jason E, Tseng, Chien-Te K, Barrett, Alan D. T, Ingram, Piers J, Brasel, Trevor, Hanson, Brendon John

“…Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-19, little is known about their mechanism(s) of action or effective dosing…”
Get full text

IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV‑2 Intervention by Blasiak, Agata, Truong, Anh T. L., Wang, Peter, Hooi, Lissa, Chye, De Hoe, Tan, Shi-Bei, You, Kui, Remus, Alexandria, Allen, David Michael, Chai, Louis Yi Ann, Chan, Conrad E.Z., Lye, David C. B., Tan, Gek-Yen G., Seah, Shirley G. K., Chow, Edward Kai-Hua, Ho, Dean

“…Nanomedicine-based and unmodified drug interventions to address COVID-19 have evolved over the course of the pandemic as more information is gleaned and virus…”
Get full text

First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults by Prativadibhayankaram, Venkateshan S., Lee, Lawrence Soon-U, Lye, David, Xiaoying, Xu, Nellore, Ranjani, Pendharkar, Vishal, Hentze, Hannes, Guan, Siyu, Ayers, Benjamin J., Seah, Shirley G. K., Chye, De Hoe, Talib, Najwa S. N., Kaliaperumal, Nivashini, Ong, Wei Yee, Wong, Zi Xin, Au, Veonice B., Alok, Anshula, Connolly, John E., Boyd-Kirkup, Jerome D., Ingram, Piers J., Hanson, Brendon J., Ethirajulu, Kantharaj, O’Connell, Damian, Chan, Conrad E. Z.

“…Introduction AOD01 is a novel, fully human immunoglobulin (Ig) G1 neutralizing monoclonal antibody that was developed as a therapeutic against severe acute…”
Get full text

Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine: e76571 by Skibinski, David AG, Hanson, Brendon J, Lin, Yufang, Messling, Veronika von, Jegerlehner, Andrea, Tee, Jason BoonSern, Chye, De Hoe, Wong, Steven KK, Ng, Amanda AP, Lee, Hui Yin

“…Influenza pandemics can spread quickly and cost millions of lives; the 2009 H1N1 pandemic highlighted the shortfall in the current vaccine strategy and the…”
Get full text